NOXXON Announces The Completion Of The First-in-Human Clinical Trial With Spiegelmer(R) NOX-A12

Unpublished

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced the successful completion of the first-in-human clinical trial with Spiegelmer® NOX-A12...